Navigation Links
Derma Sciences Reports Fourth Quarter Year-End Results for 2007
Date:4/1/2008

PRINCETON, N.J., April 1, 2008 /PRNewswire-FirstCall/ -- Derma Sciences Inc (OTC Bulletin Board: DSCI), a provider of advanced wound care products, reported that sales for 2007 were $34.1 million, an increase of 22 percent over the $27.9 million reported for 2006. Gross margins held steady at 34 percent, but due primarily to the costs of bringing in new products for the pipeline, and expanding the Company's marketing and sales staffs, the Company reported a loss of $2.3 million or $0.09 loss per share, versus a year-earlier profit or $668,739 or $0.03 per share.

Chairman and CEO Ed Quilty commented, "We believe it is important to note that sales increased significantly even though we did not launch the expanded sales force until late in the year. With world-class manufacturing in North America and China, a strong reputation for quality, some of the largest hospital suppliers in the world as customers, and proprietary wound care technologies that are unarguably the most distinctive in the industry -- Derma Sciences is in the right place at the right time."

The Company's 2007 loss included $653,012 of non-cash equity based compensation as compared to $211,756 in 2006, and $256,628 in connection with the early payoff of a credit facility during 2007. It also included $993,069 in research and development expenses, including a license fee charge of $868,069 for DSC127, a novel wound care product under development, versus none in 2006. The sales force was increased from two salespersons to nine; a national sales director was hired, as was a director of clinical affairs. Overall, general and administrative expenses increased from $4.8 million in 2006 to $6.2 million in 2007.

Subsequent Event

On March 31, 2008, the Company entered into securities purchase agreements with several accredited existing and new investors in connection with a private placement of common stock and warrants. Under the terms of the agreement, Derma will receive $6.
'/>"/>

SOURCE Derma Sciences Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
6. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
9. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
10. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
11. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... continuous operation up to 1500 bar. The sanitary design gauge of the NS2006L ... contamination. , The Pony™ NS2006L homogenizer is an ideal solution for the processing ...
(Date:7/29/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... to progressing its ground-breaking technology platforms to Phase 1 ... the Company delivers the best value for shareholders. ... said the Company currently had an extensive program of ... and academic partnerships and initiatives, and he was working ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... Shandong, China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, ... the,"Company"), one of the leading plasma-based pharmaceutical companies ... that one of its R&D,projects, "High-Purity Human Albumin," ... China. , The National ...
... Prize, Draper Laboratory, in conjunction with the National Academy of Engineering ... learn about the impact engineers have had on our daily lives, ... been awarded "Engineering,s Nobel" since 1989. , ... Cambridge, ...
... 12 Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: ... and six-month periods ended December 31, 2008. Revenues for ... compared to $3.7 million for the second quarter of ... for the three months ended December 31, 2008 compared ...
Cached Biology Technology:China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 2China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 3New Educational Website Celebrates the Accomplishments of Engineers 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 4
(Date:7/9/2015)... Calif. , July 9, 2015 /PRNewswire/ ... leading developer of human interface solutions, today ... the industry,s first fully hardware encapsulated fingerprint ... secure authentication technology is literally off the ... and biometric matching within the fingerprint sensor ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... This release is available in German . ... ago the impacts are not over yet, neither ... accident became known, KIT established working groups that are ... KIT Energy Center is supporting the energy turnaround in ...
... D.C. -- Plant science is key to addressing the major ... David Ehrhardt and Wolf Frommer. In a Perspective published in ... the development of new technology is key to transforming plant ... serve as the conduit of energy into the biosphere, provide ...
... fumes from gasoline vehicles contribute more to the production ... (SOA)-than those from diesel ,vehicles, according to a new ... in ,Environmental Sciences (CIRES), NOAA,s Earth System Research Laboratory ... found was that it wasn,t diesel engines that were ...
Cached Biology News:1 year after Fukushima 21 year after Fukushima 3The future of plant science - a technology perspective 2AGU: Gasoline worse than diesel when it comes to some types of air pollution 2
... derivative of Taq DNA polymerase. It is ... polymerase. Expressed from a gene construct in ... the 5'-3' exonuclease domain of the DNA ... active and even more heat-stable DNA polymerase ...
...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
Biology Products: